• Gene Signal International SA, of Lausanne, Switzerland, published data in Investigative Ophthalmology & Visual Science demonstrating the activity of aganirsen (GS-101, eye drops) in two models of retinal neovascular disease, wet age-related macular degeneration and ischemic retinopathy. Aganirsen is an antisense oligonucleotide that is expected to complete a Phase III trial in progressive neovascularization in the cornea this year. The data demonstrated the ability of aganirsen to reach and exert activity on the retina.